Clinical Trial Detail

NCT ID NCT01467310
Title Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212
Recruitment Completed
Gender female
Phase Phase I
Variant Requirements yes
Sponsors UNC Lineberger Comprehensive Cancer Center
Indications

Her2-receptor negative breast cancer

Therapies

Trametinib

Age Groups: adult

Additional content available in CKB BOOST